India, Feb. 5 -- EyePoint Pharmaceuticals, Inc. (EYPT) is up by 3.66 percent during Monday trading, rising $0.28 to $7.90. The stock moved higher after the company announced positive six-month results from its ongoing Phase 2 VERONA clinical trial evaluating DURAVYU, vorolanib intravitreal insert, an investigational sustained delivery therapy for retinal diseases.
EYPT is currently trading at $7.80, up $0.28 from the previous close of $7.62. The stock has fluctuated today, reaching a high of $8.68 and a low of $6.60. Trading volume has surged to 2.80 million shares, significantly above the average volume of 0.84 million. The stock remains within its 52-week range of $6.60 to $30.99.
The trial met its primary endpoint, showing an extended ...